AgenT
AgenT is developing the first blood diagnosis to detect Alzheimer's patients up to 20 years before irreversible symptoms appear. Their approach combines machine learning and multiomics biomarkers to analyze proteins and metabolites in blood plasma, decoding the body's response to Alzheimer's disease. They aim for routine blood screenings for Alzheimer's, similar to cancer screenings, believing early detection could lead to prevention. AgenT is pioneering a multiomics platform that offers early detection and identifies new therapeutic targets, equipping physicians with a blood test for the silent phase of the disease.
AgenT
AgenT is developing the first blood diagnosis to detect Alzheimer's patients up to 20 years before irreversible symptoms appear. Their approach combines machine learning and multiomics biomarkers to analyze proteins and metabolites in blood plasma, decoding the body's response to Alzheimer's disease. They aim for routine blood screenings for Alzheimer's, similar to cancer screenings, believing early detection could lead to prevention. AgenT is pioneering a multiomics platform that offers early detection and identifies new therapeutic targets, equipping physicians with a blood test for the silent phase of the disease.